вторник, 21 февраля 2017 г.

Halloran Consulting Group Advises SEEK in Preparation for First Trial ...

Halloran Consulting Group Advises SEEK in Preparation for First Trial ...


Halloran Consulting Group , a national consultancy that helps medical device, biotech, & pharma companies with FDA clinical, quality & regulatory compliance projects, announces the successful submission of an Investigational New Drug application by the National Institute of Allergy and Infectious Diseases , National Institutes of Health, for a novel vaccine designed to prevent infection of mosquito-transmitted disease, such as Zika, malaria, West Nile virus and dengue, and to hinder transmission of such infections. NIAID has initiated a Phase 1 clinical trial to test the safety of the investigational universal mosquito-borne disease vaccine and its ability to prompt an immune response.



from Biotech News